Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Edgewise Therapeutics, Inc. - Common Stock (NQ: EWTX )

26.37 -2.32 (-8.09%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,261,114
Open 28.61
Bid (Size) 25.16 (1)
Ask (Size) 27.59 (1)
Prev. Close 28.69
Today's Range 26.00 - 28.91
52wk Range 14.90 - 38.12
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025
From Edgewise Therapeutics
Via Business Wire

Performance

YTD
-2.44%
-2.44%
1 Month
+9.19%
+9.19%
3 Month
-25.36%
-25.36%
6 Month
+54.66%
+54.66%
1 Year
+35.44%
+35.44%

More News

Read More
Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
From Edgewise Therapeutics
Via Business Wire
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Via Benzinga
Dow Eyes Worst Losing Streak Since 2018
Via Talk Markets
Topics Stocks Stocks / Equities
Exposures US Equities
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Via Benzinga
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)
From Edgewise Therapeutics
Via Business Wire
Edgewise Provides Statement Regarding Company’s Relationship with Dr. Han Phan at Rare Disease Research
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
From Edgewise Therapeutics
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
From Edgewise Therapeutics
Via Business Wire
MarketBeat Week in Review – 9/23 - 9/27
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
Via MarketBeat
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Via Benzinga
Topics Economy
Exposures Interest Rates
Crude Oil Gains Over 1%; Mobileye Global Shares Jump
Via Benzinga
Exposures Fossil Fuels
Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
Via MarketBeat
Why Edgewise Therapeutics Stock Is Up 50% on Thursday
Via The Motley Fool
Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
Edgewise Therapeutics Stock Shoots Higher On Promising Early Results For Thickened Heart Treatment
Via Benzinga
Darden Restaurants Posts Q1 Results, Joins Tesla, Nvidia, XPeng And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
Via Investor's Business Daily
Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM)
From Edgewise Therapeutics
Via Business Wire
Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time
From Edgewise Therapeutics
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.